Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19

▴ Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
Vir Biotechnology, Inc. and GlaxoSmithKline plc today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in Phase 1b/2a clinical trial

Vir Biotechnology, Inc. and GlaxoSmithKline plc today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in Phase 1b/2a clinical trial. VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection.

The AGILE trial platform, which will be the first to test VIR-7832 in humans, uses adaptable protocols and statistical models to enable the evaluation of candidate medicines for COVID-19 treatment. The initiative is a collaboration between the University of Liverpool, Liverpool School of Tropical Medicine, Liverpool University Hospitals NHS Foundation Trust, University of Southampton and Lancaster University and coordinated by the National Institute for Health Research Southampton Clinical Trials Unit across the UK Clinical Research Facility Network. The trial is due to begin in the first quarter of 2021.

George Scangos, Ph.D., Chief Executive Officer of Vir, said: “We are pleased to have the support of the NHS behind our efforts to evaluate and advance VIR-7832 for the treatment and potential prevention of COVID-19. This study will be critical to our efforts as we work to understand whether the modifications we have made to this monoclonal antibody increase its potency and stimulate a T cell response to not only provide therapeutic benefits but also potentially confer a vaccine-like effect that could be applicable to prophylaxis.”

Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “While vaccine development has been very successful, current infection and hospitalization rates show that multiple vaccines and therapeutic options will be needed to combat and ultimately end this pandemic. We are grateful to everyone involved in the AGILE study for supporting this important research and expect initial results from the study to provide important insights into the use of VIR-7832 early in the course of infection with SARS-CoV-2.”

VIR-7832 is set to become the second monoclonal antibody from the Vir-GSK collaboration to be investigated as a potential COVID-19 treatment. The first antibody, VIR-7831, is currently being investigated in two global phase 3 studies; for the early treatment of COVID-19 in patients who are at high risk of hospitalization, and for the treatment of hospitalized patients with COVID-19.

Tags : #LatestPharmaNewsJan12 #LatestGskNewsJan12 #treatmentforCOVID19 #Treatmentforcoronavirus

About the Author


Sana Farid Khan

“The best way to become acquainted with a subject is to write about it."
A confident counselor, a speaker, and an educator, ready to utilize my communication skills effectively in the world of healthcare by putting pen to paper to reach new heights of success.
You can write to me at [email protected]

Related Stories

Loading Please wait...
-Advertisements-




Trending Now

Dr. Jitender Aggarwal, Founder, and CEO, Sarthak Educational Trust presses on the need for the Government to spend more on HealthcareJanuary 25, 2021
‘’Digital consultation does not have the same impact as the physical ones,’’ says Kishor Dharmy, Personal Fitness trainerJanuary 25, 2021
Making visually impaired and blind “Atma-Nirbhar” is a challenge for India - P.V.M Rao, Faculty Member, IIT DelhiJanuary 25, 2021
Fitness of the body and mind should be a constant goal says Ishani Pimpalkhare, Freelance Yoga InstructorJanuary 25, 2021
25 millions Covid-19 cases in US, UK strain more deadly says CDCJanuary 25, 2021
India reports 13,203 fresh coronavirus cases, 131 deaths; caseload at 1.06 croreJanuary 25, 2021
India reports 13,203 fresh coronavirus cases, 131 deaths; caseload at 1.06 croreJanuary 25, 2021
India reports 13,203 fresh coronavirus cases, 131 deaths; caseload at 1.06 croreJanuary 25, 2021
Cumulative number of vaccinated healthcare workers across the country more than 16 lakhJanuary 25, 2021
More than 16 lakh people administered Covid-19 vaccines in country so far: GovtJanuary 25, 2021
There is no magic formula or easy, quick fix, but it requires consistency and effort - Shameera Somani, Masters in Food Science and NutritionJanuary 25, 2021
Decoding the best ways to lose weight with Parul Malhotra Bahl, Founder, Diet ExpressionJanuary 23, 2021
Zydus Cadila receives final approval from USFDA for Liothyronine Sodium TabletsJanuary 23, 2021
Braille can be complemented by technology and not necessarily replaced says Ketan Kothari, Manager – Advocacy, Sightsavers IndiaJanuary 23, 2021
’50 – 60% of the population have uncontrolled blood sugar levels,’’ says Dr. Abhijit Bhograj, Co-founder and CMO, 7 SugarJanuary 23, 2021
Govt. uses Rapid Assessment System, RAS for taking feedback from people vaccinated for COVID-19January 23, 2021
Cumulative number of vaccinated Healthcare Workers across the country has surpasses 12.7 lakh January 23, 2021
India's coronavirus count increases by 14,256 fresh cases; 152 deaths reported in 24 hrsJanuary 23, 2021
Pfizer and BioNTech reach agreement with COVAX for advance purchase of Vaccine to Help Combat COVID-19January 23, 2021
In life, there are no shortcuts says Honnesh Kamaria, Yoga and Fitness Instructor, TheYogaShrineJanuary 22, 2021